doi:10.11852/zgetbjzz2024-0988

Abstract

CLC Number:

R722.1
R450

梁雁, 罗小平. 遗传代谢病的治疗进展[J]. 中国儿童保健杂志, 2024, 32(9): 929-933.

[1] Ferreira CR,Rahman S,Keller M,et al.An international classification of inherited metabolic disorders (ICIMD)[J].J Inherit Metab Dis,2021,44(1):164-177.
[2] Turner A,Glinton KE,Sutton VR.Advancements in therapeuticsfor inborn errors of metabolism[J].Curr Opin Pediatr,2022,34(6):559-564.
[3] Vernon HJ, Manoli I.Milestones in treatments for inborn errors of metabolism:Reflections on where chemistry and medicine meet[J].Am J Med Genet A,2021,185(11):3350-3358.
[4] Weinreb NJ,Goldblatt J,Villalobos J,et al.Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment[J].J Inherit Metab Dis,2013,36(3):543-553.
[5] Rastall DPW,Amalfitano A.Current and future treatments for lysosomal storage disorders[J].Curr Treat Options Neurol,2017,19(12):45.
[6] Parenti G,Andria G,Ballabio A.Lysosomal storage diseases:From pathophysiology to therapy[J].Annu Rev Med,2015,66:471-486.
[7] Kaplan P,Baris H,De Meirleir L,et al.Revised recommendations for the management of Gaucher disease in children[J].Eur J Pediatr,2013,172(4):447-458.
[8] Sifuentes M,Doroshow R,Hoft R,et al.A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years[J].Mol Genet Metab,2007,90(2):171.
[9] Zhu DQ,Zhu JC,Qiu WJ,et al.A Multi-centre prospective study of the efficacy and safety of alglucosidase alfa in chinese patients with infantile-onset pompe disease[J].Front Pharmacol,2022,13:903488.
[10] Sifuentes M,Doroshow R,Hoft R,et al.A follow-up study of MPS I patients treated with laronidase enzymereplacement therapy for 6 years[J].Mol Genet Metab,2007,90(2):171.
[11] Ebbink BJ,Poelman E,Aarsen FK,et al.Classic infantile Pompe patients approaching adulthood:A cohort study on consequences for the brain[J].Dev Med Child Neurol,2018,60(6):579.
[12] Critchley BJ,Gaspar HB,Benedetti S.Targeting the central nervous system in lysosomal storage diseases:Strategies to deliver therapeutics across the blood-brain barrier[J].Mol Ther,2023,31(3):657-675.
[13] Lewis G,Morrill AM,Conway-Allen SL,et al.Review ofcerliponase alfa:Recombinant human enzyme replacement therapy for late-infantile neuronal ceroid lipofuscinosis type 2 [J].J Child Neurol,2020,35(5):348.
[14] Schulz A,Ajayi T,Specchio N,et al.CLN2study group.Study of intraventricular cerliponase alfa for CLN2 disease[J].N Engl J Med,2018,378(20):1898.
[15] Nestrasil I,Shapiro E,Svatkova A,et al.Intrathecal enzyme replacement therapy reverses cognitive declinein mucopolysaccharidosis type I[J].Am J Med Genet A,2017,173(3):780.
[16] van Gelder CM,Poelman E,Plug I,et al.Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease:An open-label single-center study [J].J Inherit Metab Dis,2016,39(3):383.
[17] Cohen JL,Chakraborty P,Fung-Kee-Fung K,et al.Inutero enzyme-replacement therapy for infantile-onset Pompe's disease[J].N Engl J Med,2022,387(23):2150-2158.
[18] Platt FM,d'Azzo A,Davidson BL,et al.Lysosomal storage diseases[J].Nat Rev Dis Primers,2018,4(1):27-52.
[19] Taylor M,Khan S,Stapleton M,et al.Hematopoieticstem cell transplantation for mucopolysaccharidoses:Past,present,and future [J].Biol Blood Marrow Transplant,2019,25(7):e226-e246.
[20] Prasad VK,Kurtzberg J.Transplant outcomes in mucopolysaccharidoses[J].Semin Hematol,2010,47(1):59-69.
[21] Guffon N,Guffon N,Pettazzoni M,et al.Long term disease burden post-transplantation:Three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT) [J].Orphanet J Rare Dis,2021,16(1):60.
[22] Allewelt H,Taskindoust M,Troy J,et al.Long-term functional outcomes after hematopoietic stem cell transplant for early infantile krabbe disease[J].Biol Blood Marrow Transplant,2018,24(11):2233-2238.
[23] Yoon IC,Bascou NA,Poe MD,et al.Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease[J].Blood,2021,137(13):1719-1730.
[24] Donald A,Björkvall CK,Vellodi A,et al.Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease[J].Orphanet J Rare Dis,2022,17(1):234.
[25] Brunetti-Pierri N,Ferla R,Ginocchio VM,et al.Liver-directed adeno-associated virus-mediated gene therapy for mucopolysaccharidosis type Ⅵ[J].NEJM Evid,2022,1(7):EVIDoa2200052.
[26] Hannah WB,Case LE,Smith EC,et al.Screening data from 19 patients with late-onset Pompe disease for a phase Ⅰ clinical trial of AAV8 vector-mediated gene therapy[J].JIMD Rep,2023,64(5):393-400.
[27] Jensen TL,Gøtzsche CR,Woldbye DPD.Current andfuture prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord[J].Front Mol Neurosci,2021,14:695937.
[28] Biffi A,Montini E,Lorioli L,et al.Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy[J].Science,2013,341:1233158.
[29] Fumagalli F,Calbi V,Natali Sora MG,et al.Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy:Long-term results from a non-randomised,open-label,phase 1/2 trial and expanded access[J].Lancet,2022,399(10322):372-383.
[30] Khan A,Barber DL,Huang J,et al.Lentivirus-mediated gene therapy for Fabry disease [J].Nat Commun,2021,12(1):1178.
[31] Enquist IB,Nilsson E,Ooka A,et al.Effective cell and gene therapy in amurine model of Gaucher disease[J].Proc Natl Acad Sci U S A,2006,103:13819.
[32] Baek R,Coughlan K,Jiang L,et al.Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia,methylmalonic acidemia,and phenylketonuria[J].Nat Commun,2024,15(1):3804.
[33] Kwon JH,Lee YM,Cho JH,et al.Liver-directed gene therapy for murine glycogen storage disease type Ib [J].Hum Mol Genet,2017,26:4395.
[34] Leal AF,Fnu N,Benincore-Flórez E,et al.The landscape of CRISPR/Cas9 for inborn errors of metabolism [J].Mol Genet Metab,2023,138(1):106968.
[35] McCafferty EH,Scott LJ.Migalastat:A review in fabry disease[J].Drugs,2019,79(5):543-554.
[36] Ficicioglu C.Review of miglustat for clinical management in Gaucher disease type 1[J].Ther Clin Risk Manag,2008,4(2):425-431.
[37] Patterson MC,Vecchio D,Prady H,et al.Miglustat for treatment of Niemann-Pick C disease:A randomised controlled study[J].Lancet Neurol,2007,6(9):765-772.
[38] Mengel E,Patterson MC,Da Riol RM,et al.Efficacy and safety of arimoclomol in Niemann-Pick disease type C:Results from a double-blind,randomised,placebo-controlled,multinational phase 2/3 trial of a novel treatment[J].J Inherit Metab Dis,2021,44(6):1463-1480.
[39] Belmatoug N,Di Rocco M,Fraga C,et al.Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe[J].Eur J Intern Med,2017,37:25-32.
[40] Becquemont L.Type 1 Gaucher disease (CYP2D6-eliglustat)[J].Therapie,2017,72(2):323-326.
[41] Daniotti M,la Marca G,Fiorini P,et al.New developments in the treatment of hyperammonemia:Emerging use of carglumic acid [J].Int J Gen Med,2011,4:21-28.
[42] Yap S,Lamireau D,Feillet F,et al.Real-world experience of carglumic acid for methylmalonic and propionic acidurias:An interim analysis of the multicentre observational PROTECT study[J].Drugs RD,2024,24(1):69-80.
[43] Narita A,Shirai K,Itamura S,et al.Ambroxol chaperone therapy for neuronopathic Gaucher disease:A pilot study[J].Ann Clin Transl Neurol,2016,3(3):200-215.
[44] Zhan X,Zhang H,Maegawa GHB,et al.Use ofambroxol as therapy for gaucher disease[J].JAMA Netw Open,2023,6(6):e2319364.
[45] Istaiti M,Revel-Vilk S,Becker-Cohen M,et al.Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson:Investigator initiated registry based on real life data[J].Am J Hematol,2021,96(5):545-551.

遗传代谢病的治疗进展

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	CUI Pengyuan, LI Guiping. Causal relationship between neonatalhy perbilirubinemia and tic disorder by Mendelian randomization [J]. Chinese Journal of Child Health Care, 2024, 32(10): 1116-1121.
[2]	WEI Ping, WEI Jishan, HUANG Xuhua, ZHANG Yuxing, LIU Xianghong, HE Zhongbiao, MO Jingyuan, HUANG Zengshuai, YU Qun. Application of cardiac auscultation, pulse oximetry combine with oxygen inhalation in screening neonatal congenital heart disease in Guangxi Province [J]. Chinese Journal of Child Health Care, 2024, 32(9): 1034-1039.
[3]	HUANG Wanyi, ZHANG Youxiang, OU Qiaoqun, LIU Yuanchun, GUO Jiayu. Effects of gestational diabetes mellitus on brain development and miRNAs expression profile in neonatal mice [J]. Chinese Journal of Child Health Care, 2024, 32(2): 154-158.
[4]	LU Anfeng, HUANG Peilu, BI Lei, HUANG Guosheng, HUANG Haiyan. Physical and neuropsychological development of the offspring born to mother with gestational diabetes mellitus at 2 years old [J]. Chinese Journal of Child Health Care, 2024, 32(2): 208-211.
[5]	WEI Jufang, CHEN Jijian. Trends and influencing factors of low birth weight of newborns in Xixiangtang District, Nanning City from 2015 to 2021 [J]. Chinese Journal of Child Health Care, 2023, 31(7): 785-789.
[6]	. [J]. Chinese Journal of Child Health Care, 2023, 31(2): 225-228.
[7]	CHEN Yu-xia, LIU Hua-yan, FAN Qian-qian. Changes of neuron specific enolase, transcutaneous hour bilirubin, total bilirubin/albumin levels in full-term infants with hyperbilirubinemia and their correlation with long-term neurodevelopment [J]. Chinese Journal of Child Health Care, 2023, 31(1): 86-90.
[8]	ZHANG Du-fei, ZHANG Xiang-yun. Epidemiological survey on neonatal congenital heart disease in Hainan Province in 2020 [J]. Chinese Journal of Child Health Care, 2023, 31(1): 91-95.
[9]	WANG Hui-ping, WANG Li, GAO Qiong, BAI Bo-liang, MA Ying-jun. Physical and neurological development of necrotizing enterocolitis in very low birth weight infants [J]. Chinese Journal of Child Health Care, 2023, 31(1): 96-100.
[10]	LIANG Li-yu, ZHU Hui. Prognosis of neonates with mild hyperthyrotropinemia [J]. Chinese Journal of Child Health Care, 2022, 30(12): 1409-1413.
[11]	LIANG Sui-xin, TI Yun-xing, HUANG Jun-rong, LI Xiu-hong, ZHOU Wen-jia. Protective effect and mechanism of delayed mild hypothermia on white matter injury inoxygen-glucose deprivation and restoration newborn rats [J]. Chinese Journal of Child Health Care, 2022, 30(10): 1083-1087.
[12]	LIU Jian-hong, HUANG Fang. Association of serum NFP and Nrf2 levels with early brain injury in neonatal asphyxia [J]. Chinese Journal of Child Health Care, 2022, 30(7): 787-791.
[13]	DONG Li-ping, ZHANG Zhen, CUI Yan-guo, LI Qing-bo. Application of screening indices for methylmalonic acidemia in Zibo city [J]. Chinese Journal of Child Health Care, 2022, 30(7): 792-795.
[14]	ZHOU Li-xia, CAI Dong, CHEN You-ping. Effect of melatonin regulating Akt/mTOR signal pathway on intestinal barrier function in neonatal rats with necrotizing enterocolitis [J]. Chinese Journal of Child Health Care, 2022, 30(6): 622-626.
[15]	. [J]. Chinese Journal of Child Health Care, 2022, 30(6): 694-696.